Thus, the use of this nutraceutical in a pill formula for systemic applications could be further envisioned as immunomodulant agent for the adjuvant therapy (during or after chemotherapeutics) with the aim to restore the innate immune response in those solid tumors characterized by immunosuppression driven by PI3K-Akt and TGF-β pathways dysregulation (e.g., brain tumors, medulloblastoma [117, 118] and triple negative breast cancer [119]), once tested its pharmacokinetics and tissue biodistribution in vivo. This evidence concerns the gene TGFB1 and triple-negative breast carcinoma.